| Not Yet Recruiting | GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer NCT07489287 | Roswell Park Cancer Institute | Phase 1 |
| Not Yet Recruiting | Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer NCT07265739 | Massachusetts General Hospital | Phase 2 |
| Recruiting | A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. NCT07470853 | Whitehawk Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) NCT07109414 | Novita Pharmaceuticals, Inc. | Phase 2 / Phase 3 |
| Recruiting | Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants W NCT07444814 | Whitehawk Therapeutics, Inc. | Phase 1 |
| Recruiting | A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer NCT07226427 | Stemline Therapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Res NCT07117877 | Fudan University | Phase 2 |
| Not Yet Recruiting | Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Can NCT06973421 | Fudan University | Phase 2 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer NCT07030907 | Outpace Bio, Inc. | Phase 1 |
| Recruiting | A Study of Lorigerlimab in Participants With Advanced Solid Tumors NCT06730347 | MacroGenics | Phase 2 |
| Active Not Recruiting | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Pla NCT06619236 | Genmab | Phase 3 |
| Recruiting | A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagoni NCT06710288 | ImmunityBio, Inc. | Phase 2 |
| Recruiting | Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer NCT06321484 | Dana-Farber Cancer Institute | Phase 1 |
| Recruiting | A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer NCT06315491 | Cybrexa Therapeutics | Phase 2 |
| Recruiting | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NCT06586957 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha NCT06547840 | Epsilogen Ltd | Phase 1 |
| Recruiting | A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors NCT06515613 | Context Therapeutics Inc. | Phase 1 |
| Recruiting | A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470 | MacroGenics | Phase 1 |
| Terminated | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NCT06264921 | NiKang Therapeutics, Inc. | Phase 1 |
| Terminated | Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer NCT05756907 | Sonnet BioTherapeutics | Phase 1 / Phase 2 |
| Terminated | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Cho NCT05870748 | Sutro Biopharma, Inc. | Phase 2 / Phase 3 |
| Terminated | A Biomarker Screening Protocol for Participants With Solid Tumors NCT05891197 | Lyell Immunopharma, Inc. | — |
| Withdrawn | Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer NCT05736952 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Phase 2 |
| Completed | Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer NCT05494580 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Recruiting | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherap NCT05281471 | Genelux Corporation | Phase 3 |
| Completed | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers NCT05483933 | Shattuck Labs, Inc. | Phase 1 |
| Recruiting | Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Peg NCT05271318 | TILT Biotherapeutics Ltd. | Phase 1 / Phase 2 |
| Terminated | A Study to Investigate LYL797 in Adults With Solid Tumors NCT05274451 | Lyell Immunopharma, Inc. | Phase 1 |
| Unknown | Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer NCT05310344 | Lei Li | Phase 2 |
| Completed | A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer NCT05198804 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab NCT05081609 | Ascendis Pharma Oncology Division A/S | Phase 1 / Phase 2 |
| Terminated | Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithe NCT05092360 | Mural Oncology, Inc | Phase 3 |
| Terminated | A Study of DeTIL-0255 in Adults With Advanced Malignancies NCT05107739 | Nurix Therapeutics, Inc. | Phase 1 |
| Recruiting | A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer NCT04787289 | British Columbia Cancer Agency | Phase 2 |
| Terminated | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced NCT04851834 | Xennials Therapeutics Australia Pty Ltd | Phase 1 / Phase 2 |
| Terminated | Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent NCT04729608 | Aravive, Inc. | Phase 3 |
| Terminated | A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer NCT04718376 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 |
| Unknown | Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial) NCT04678102 | Seoul National University Hospital | Phase 1 |
| Terminated | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) NCT04504916 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Recruiting | IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer NCT05551507 | InxMed (Shanghai) Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian NCT04374630 | Laekna Limited | Phase 2 |
| Unknown | Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer NCT04376073 | Jihong Liu | Phase 2 |
| Unknown | Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cance NCT05979298 | CureLab Oncology | Phase 2 |
| Completed | First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b NCT06517485 | Mersana Therapeutics | Phase 1 |
| Active Not Recruiting | Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer NCT03949283 | Cordgenics, LLC | Phase 3 |
| Unknown | Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer NCT03542669 | Peking University People's Hospital | Phase 1 |
| Completed | Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian NCT03552471 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Completed | First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b NCT06517433 | Mersana Therapeutics | Phase 1 |
| Active Not Recruiting | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b NCT03319628 | Mersana Therapeutics | Phase 1 / Phase 2 |
| Terminated | FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovaria NCT02641639 | Mateon Therapeutics | Phase 2 / Phase 3 |
| Terminated | Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer NCT02575807 | Aduro Biotech, Inc. | Phase 1 / Phase 2 |
| Completed | H.O.P.E: Helping Ovarian Cancer Patients Cope NCT02090582 | Duke University | N/A |
| Completed | A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer NCT01711970 | Vascular Biogenics Ltd. operating as VBL Therapeutics | Phase 1 / Phase 2 |